# Phase 3 Leukemia, Lymphocytic: 20 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 3 for Leukemia, Lymphocytic, Chronic, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Leukemia, Lymphocytic, Chronic, B-Cell trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/leukemia-lymphocytic-chronic-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2026 | NCT07753369 | A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753369) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| May 12, 2026 | NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency... | Grifols Biologicals, LLC | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582432) |
| April 7, 2026 | NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Nurix Therapeutics, Inc. | Phase 3 | Recruiting | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516093) |
| January 15, 2026 | NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL | Newave Pharmaceutical Inc | Phase 3 | Recruiting | CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL... | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342478) |
| January 7, 2026 | NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Alliance for Clinical Trials in Oncology | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 466 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321652) |
| December 11, 2025 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With... | BeOne Medicines | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277231) |
| August 24, 2025 | NCT07139873 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | Dizal Pharmaceuticals | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139873) |
| July 24, 2025 | NCT07082452 | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | Not yet recruiting | Leukemia, B-Cell, Chronic, Leukemia | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082452) |
| May 15, 2025 | NCT06973187 | A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory... | BeOne Medicines | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06973187) |
| April 24, 2025 | NCT06943872 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax... | BeOne Medicines | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943872) |
| February 26, 2025 | NCT06846671 | A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small... | BeOne Medicines | Phase 3 | Recruiting | CLL, Chronic Lymphocytic Leukemia, SLL | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846671) |
| May 24, 2024 | NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With... | AbbVie | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06428019) |
| May 2, 2024 | NCT06395441 | Wisconsin Ginseng for Decreasing Cancer Related Fatigue | Mayo Clinic | Phase 3 | Recruiting | Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma... | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395441) |
| November 18, 2023 | NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06136559) |
| July 17, 2023 | NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small... | 735 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05947851) |
| December 9, 2022 | NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05645107) |
| February 24, 2022 | NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma... | Loxo Oncology, Inc. | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 737 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05254743) |
| January 19, 2022 | NCT05197192 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With... | German CLL Study Group | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05197192) |
| February 17, 2020 | NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL... | National Cancer Institute (NCI) | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04269902) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 4 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| German CLL Study Group | 1 |
| Loxo Oncology, Inc. | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| [Grifols Therapeutics LLC](https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc) | 1 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Mayo Clinic | 1 |
| [CSL Behring](https://specstream.ai/data/clinical-trials/company/csl-behring) | 1 |
| National Cancer Institute (NCI) | 1 |
| Nurix Therapeutics, Inc. | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Grifols Biologicals, LLC | 1 |
| Newave Pharmaceutical Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| Germany | 9 |
| France | 9 |
| United Kingdom | 9 |
| Australia | 8 |
| Canada | 8 |
| Poland | 8 |
| Spain | 8 |
| Brazil | 7 |
| China | 7 |
| Italy | 7 |
| Belgium | 6 |
| Czechia | 6 |
| New Zealand | 6 |
| Argentina | 5 |
| South Korea | 5 |
| Japan | 5 |
| Netherlands | 4 |
| Sweden | 4 |
| Israel | 4 |
| Taiwan | 4 |
| Turkey (Türkiye) | 4 |
| Austria | 3 |
| Denmark | 3 |
| Chile | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Trinidadian restaurants in the United States](https://specstream.ai/data/businesses/trinidadian-restaurants/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Middle Eastern restaurants in the United States](https://specstream.ai/data/businesses/middle-eastern-restaurants/united-states)
- [Wallpaper installers in the United States](https://specstream.ai/data/businesses/wallpaper-installers/united-states)
